Compare AstraZeneca plc (AZN) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? AstraZeneca plc trades at $166.61 (market cap $253.13B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.68. The key difference: AstraZeneca plc pays a 1.92% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SPUS | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $59.51 |
52-Week Low | $137.44 | $45.13 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SPUS trades at $57.00, down 1.35% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock is near key support at $57. Recent dividends of $0.03 per share were declared for April, May, and June 2026, reflecting income distribution. News highlights institutional buying and the strength of dividend strategies in U.S. markets.
Outlook remains supported by dividend focus and institutional interest, but limited fundamental data and reliance on broader market trends pose risks. Investors should weigh income benefits against exposure to equity market volatility and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
